Sign up USA
Proactive Investors - Run By Investors For Investors

Marinus Pharmaceuticals Inc shares soar on early study results

Enrollment is continuing in the study with top-line data expected in mid-2017
Marinus Pharmaceuticals Inc shares soar on early study results
The data comes from initial CDKL5 patients enrolled in an ongoing Phase 2 open-label study, the company said

Shares in Marinus Pharmaceuticals Inc (NASDAQ: MRNS) shot up almost 40% as it posted positive clinical study findings.

The data comes from initial CDKL5 patients enrolled in an ongoing Phase 2 open-label study evaluating its ganaxolone candidate as a treatment for orphan, genetic disorders.

CDKL5 is a severe, rare genetic disorder that results in early-onset, difficult-to-control seizures.

Enrollment is continuing in the study with top-line data expected in mid-2017.

“We are encouraged by the results in these difficult-to-treat pediatric patients,” said Dr. Jaakko Lappalainen, vice president of clinical development at the company.

“Concurrent with completing this study, we will be evaluating the potential for breakthrough therapy and applying for orphan drug designation with the United States Food and Drug Administration.

"CDKL5 pediatric epilepsy may prove to be an attractive and efficient path for ganaxolone and we look forward to evaluating results from the final patients enrolled in this cohort of the study.”

Shares in New York are at US$1.61 - an increase of 38.79% at the time of writing.



Register here to be notified of future MRNS Company articles
View full MRNS profile

Marinus Timeline

Related Articles

A graphic of a tumour growing in the body
July 07 2016
Nanobiotix is a late clinical-stage nanomedicine company researching novel approaches to enhance radiotherapy for the local treatment of cancer.
ANGLEplc.jpg
18:00
Find out more from Dr James Garner at Proactive's CEO Sessions.
Pollen2.jpg
January 19 2017
Turnover was £40.4mln in the six months to December
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use